Cargando…
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers
INTRODUCTION: Immune checkpoint inhibitors (ICI) have become a primary treatment modality for patients with a variety of malignancies. Given their increasing use, it is essential to be familiar with their immune-related adverse events (irAEs). Here we report a severe case of autoimmune hemolytic ane...
Autores principales: | Jain, Natasha A, Zhao, Songzhu, Wei, Lai, Rogers, Kerry A, Otterson, Gregory A, Wang, Tzu-Fei, Owen, Dwight H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680604/ https://www.ncbi.nlm.nih.gov/pubmed/33235503 http://dx.doi.org/10.2147/CMAR.S264166 |
Ejemplares similares
-
Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors
por: Owen, Dwight H., et al.
Publicado: (2019) -
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
por: Haddad, Tyler C., et al.
Publicado: (2021) -
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer
por: Owen, Dwight H., et al.
Publicado: (2018) -
Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)